Digest Network Come funziona
Network
/
Società
Re
Non verificato

ReAlta Life Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

15 comunicati stampa

Guarda tutti i comunicati
06/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
ReAlta Life Sciences to Present RLS-0071 (pegtarazimod) Clinical Data at 2025 American Society of Hematology Annual Meeting
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
21/08/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
ReAlta Life Sciences Receives EMA Orphan Drug Designation for RLS-0071 (pegtarazimod) for the Treatment of Graft-Versus-Host Disease
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
28/07/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
ReAlta Life Sciences Strengthens Management Team with the Appointment of Biotechnology Business Leader Ellen Lubman, MBA as Chief Business Officer
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
22/07/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
ReAlta Life Sciences Publishes Data Demonstrating RLS-0071 (pegtarazimod) Reduces Brain Inflammation in Preclinical Hypoxic Ischemic Encephalopathy Model
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
19/05/2025
Eventi
Fiere
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
ReAlta Life Sciences Announces New Inflammatory Biomarker Data from Acute Exacerbations of Chronic Obstructive Pulmonary Disease Program at American Thoracic Society 2025 International Conference
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
25/04/2025
Eventi
Fiere
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ReAlta Life Sciences Announces New Clinical Data for RLS-0071 (pegtarazimod) from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
08/04/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ReAlta Life Sciences to Present New Clinical Data from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
01/04/2025
Mercato del lavoro
Biotecnologia
Salute
Scienza
Farmaceutica
ReAlta Life Sciences Announces Appointment of Distinguished Immunologist, Laurie Glimcher, M.D., to Board of Directors
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
25/02/2025
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Mercato del lavoro
ReAlta Life Sciences Announces Appointment of Biotechnology Leader Andrew Miller, Ph.D., to Board of Directors
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0
08/12/2024
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
ReAlta Life Sciences Announces Positive Preclinical Data for RLS-0071 (pegtarazimod) in Acute Graft-Versus-Host Disease (aGVHD) at American Society of Hematology Annual Meeting
Fonte
ReAlta Life Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0